We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liquid Biopsy and Lung Cancer.
- Authors
Pisapia, Pasquale; Malapelle, Umberto; Troncone, Giancarlo
- Abstract
The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including EGFR, ALK, ROS-1, and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are difficult to reach or when multiple analyses are necessary to monitor tumor progression and treatment response, liquid biopsy is a valid noninvasive alternative. This analysis, which is preferentially performed on circulating tumor DNA (ctDNA) extracted from plasma samples, has the major advantage of reducing the inherent risks and discomfort of tissue biopsy. However, a major disadvantage is that it yields only a low number of ctDNA targets. Thus, to avoid false-positive and false-negative results, it is important to adopt and validate technologies with high sensitivity and specificity in the pre-analytical phase of sampling. This review succinctly addresses the principal methodologies for analyzing plasma-derived ctDNA in NSCLC patients.
- Subjects
LUNG cancer diagnosis; NUCLEIC acid analysis; DNA analysis; BIOMARKERS; BODY fluid examination; DIAGNOSTIC errors; EPIDERMAL growth factor; EXTRACELLULAR space; ONCOGENES; POLYMERASE chain reaction; DISEASE progression; ANAPLASTIC lymphoma kinase
- Publication
Acta Cytologica, 2019, Vol 63, Issue 6, p489
- ISSN
0001-5547
- Publication type
Article
- DOI
10.1159/000492710